Medical NewsGerman Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Inactivated viruses / inactivated surface antigens (vaccines). |
| Generic Name : | Hepatitis A / typhoid vaccine |
| Drug description : | Suspension for injection in a glass pre-filled syringe. |
| Presentation : | Suspension for injection, combined inactivated hepatitis A (HM175 hepatitis A strain) and purified Vi polysaccharide typhoid vaccine (extracted from Salmonella typhi Ty2 strain). Each 1mL dose contains 25 microgram s of the Vi polysaccharide of Salmonella typhi and not less than 1,440 ELISA units (EL.U) of inactivated hepatitis A viral antigen. |
| Indications : | Active immunisation against hepatitis A virus infection and typhoid fever for both adults and adolescents 15 years of age and older. |
| Adult Dosage : | Administer by intramuscular injection in the deltoid region. Primary vaccination: A single dose of 1mL given at least two weeks prior to risk of exposure to typhoid and preferably one month prior to exposure to hepatitis A. exposure to hepatitis A. Booster vaccination: A booster dose of hepatitis A vaccine is recommended any time between six and 12 months after a single dose of Hepatyrix in order to ensure long term protection against hepatitis A. Hepatyrix may also be given as a single dose of 1mL for booster vaccination between six and 12 months following primary immunisation with hepatitis A vaccine. Subjects who remain at risk of typhoid fever should be re- vaccinated using a single dose of Vi polysaccharide vaccine, every three years. |
| Child Dosage : | Not recommended under 15 years of age. |
| Contra Indications : | Known hypersensitivity to any component of the vaccine, or subjects having shown hypersensitivity after previous administration of Hepatyrix or monovalent vaccines Typherix and Havrix. |
| Special Precautions : | Postpone vaccination in acute severe febrile illness. Use with caution in patients with hypersensitivity to neomycin. Pregnancy and lactation. See Summary of Product Characteristics. |
| Adverse Reactions : | Injection site reactions, including pain, erythema and swelling. Systemic effects including malaise, headache, general aches, nausea, itching and fever. Very rarely, allergic reactions. |
| Manufacturer : | GlaxoSmithKline(GSK) |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org